Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients：a Randomized, Open-label, Phase 3 Study

NCT02085655 is registered in ClinicalTrials.gov with Huiqiang Huang as lead sponsor.

NCT NCT02085655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02085655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients：a Randomized, Open-label, Phase 3 Study
Lead sponsor
Huiqiang Huang
Phase
Phase 3
Overall status
Unknown status
Start date
April 25, 2013
Completion date
December 31, 2022
Enrollment
264 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal nk-t-cell lymphoma, nasal and nasal-type